Clene Inc. (CLNN) Form 8-K — Oct 19, 2026
Clene Inc. entered into a subaward amendment on October 15, 2026 for the fourth year of its NIH grant, obligating up to $7.2 million for the period September 1, 2026 through August 31, 2027. The funding comes through NYU Grossman School of Medicine as prime awardee under a four-year, $45.1 million NIH grant, bringing total funds obligated to Clene to $15.3 million to date.
Key figures
- Deal Value Usd
- 7214420
- Fa rate
- 15%
- Direct costs
- 6273409
- Indirect costs
- 941011
- Nih grant total
- $45.1 million over four years
- Funded this action
- 7214420
- Total obligated to date
- 15258081
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.